Exact Sciences Corporation (EXAS)
Fair ValueFundamental
39
Price
$-
Market Cap
$20.03B
Part 1 · What the company is worth
Overview
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. It offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer; Cologuard Plus Tests; Cancerguard Test; and Genetic Testing. The company also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; Oncodetect Test;OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Riskguard Test, a hereditary cancer test to understand their inherited risk of cancer. Its pipeline focus on advancing screening and diagnostic products, including risk assessment, screening and prevention, early disease diagnosis, adjuvant and/or neoadjuvant disease treatment, metastatic disease treatment selection, and recurrence monitoring. The company has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University, as well as Freenome Holdings, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
Generated with artificial intelligence on September 21, 2026, shared with all users
Competes directly in colorectal cancer blood-based screening (Shield test) and multi-cancer early detection across the same patient population as Exact Sciences' Cologuard and Cancerguard tests.
Competes in molecular residual disease (MRD) testing with Signatera and multi-cancer early detection, serving the same oncology clinicians and cancer patients as Exact Sciences' precision oncology portfolio.
Competes in breast cancer recurrence risk scoring (Prosigna test) and prognostic assessment, serving the same population of breast cancer patients and oncologists as Exact Sciences' Oncotype DX-related offerings.
Competes in precision oncology testing including recurrence risk assessment and MRD testing, alongside genetic testing, for the same population of cancer patients and oncologists served by Exact Sciences.
Competes in multi-cancer early detection blood testing (Caris Detect) and comprehensive tumor profiling for treatment selection, addressing the same patient screening and precision oncology needs as Exact Sciences.
Balance Sheet & Liquidity
Revenue
$3.25B
Fiscal year ended 12/31/2025
Net Income
$-208M
Fiscal year ended 12/31/2025
Free Cash Flow
$282M
Total Equity
$2.40B
Total Liabilities
$2.53B
Current Ratio
2.43
Interest Coverage
-
Debt/EBITDA
35.47
Earnings Per Share
Revenue & Net Income
Free Cash Flow
Income Breakdown
Historical statement
Margins over time
Debt over time
How heavy the debt is
Growth grid
Growth — Revenue
Fair Value Estimation
Fair Value
$76.95
Current Price
-
Margin of Safety
-
Fair Value Range
$50.02 - $103.88
Spread across the valuation methods used, not a statistically calibrated confidence interval.
Estimation Methods
Valuation Metrics
P/E Ratio
-
ROE
-8.7%
P/B Ratio
8.34
P/FCF
-
Gross Margin
69.7%
ROIC
-4.8%
Profitability Radar
Value Creation (Economic Moat)
ROIC
-4.8%
WACC
7.1%
ROIC − WACC
-11.9 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Fundamental Analysis Criteria
Passed (7)
- Price CAGR 22.89%
- Gross margin 69.7%
- Debt/equity ratio
- Positive free cash flow
- Current ratio
- Revenue growth 5Y 16.8%
- Net margin trend -6.4% vs -37.3%
Failed (8)
- ROIC -4.8%
- P/B ratio 8.34
- CapEx intensity
- Debt/EBITDA
- DCF valuation (Unknown)
- ROE -8.5%
- Earnings surprise, average -111.7%
- Piotroski F-Score 2/9
Unavailable (11)
- EPS data insufficient
- P/FCF –
- Dividend payout –
- Operating margin –
- Interest coverage
- Return on tangible assets
- Low reliance on intangibles
- Price below Graham Number
- PEG ratio (needs P/E > 0 and growth > 0)
- Earnings quality (operating cash flow / net income)
- Share dilution (missing share count)
Piotroski F-Score
Serious financial concerns
Earnings Quality
Low quality: investigate accounting
Share Dilution
Buying back shares. Shareholder friendly
Institutional Holdings
No institutional filings reported for this company.
Governance
Audit Risk
1
Board Risk
2
Compensation Risk
3
Shareholder Rights Risk
4
Part 2 · The price and its context
This part shows how the price has behaved, not whether the company is worth owning. Inside: technical analysis, potential, historical drawdowns, gamma exposure.
Market Reaction Profile
How much EXAS moves, measured on its daily prices.
Not enough price history to measure the volatility of EXAS yet.
Earnings reactions
How EXAS moved around its past quarterly results.
No earnings releases recorded yet for EXAS. This can happen with recent listings or with companies that do not file 8-K reports with the SEC.
Historical statistics for educational purposes only. They are not forecasts and not investment advice.
Price reaction to the news
Latest news on EXAS and what the price did next.
Return of the stock minus return of SPY over the same days. A news item close to a price move did not necessarily cause it. Historical data for educational purposes only, not investment advice.
Latest News
Recent headlines for EXAS.
- 2/23/2026POSITIVEAbbott Laboratories Kicks Off Bond Sale for Exact Sciences Deal
Abbott Laboratories is launching a significant bond sale, in as many as eight parts, to fund its approximately $21 billion acquisition of cancer-screening company Exact Sciences Corp. This move signals Abbott's strong commitment to finalizing a strategic deal that will bolster its diagnostics portfolio. For shareholders of Exact Sciences, this development is a clear positive catalyst. Acquisitions of this magnitude are typically executed at a premium to the target's current market price, suggesting an immediate upward revaluation of the stock. Abbott's financing action validates the technology and growth potential of Exact Sciences, turning the company's intrinsic value into a tangible gain for investors as the deal progresses.